Beam Therapeutics Ended Q1 2024 With $1.1B In Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans Into 2027
Beam Therapeutics Ended Q1 2024 With $1.1B In Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans Into 2027
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.